江苏吉贝尔药业股份有限公司 募集资金年度存放与使用情况鉴证报告 2023 年度 募集资金年度存放与使用情况鉴证报告 | 索引 | | 页码 | | --- | --- | --- | | 鉴证报告 | | 1-2 | | 关于募集资金 2023 | 年度存放与使用情况的专项报告 | 1-9 | XYZH/2024SHAA2B0060 江苏吉贝尔药业股份有限公司 江苏吉贝尔药业股份有限公司全体股东： 我们对后附的江苏吉贝尔药业股份有限公司(以下简称 吉贝尔公司)关于募集资金 2023 年度存放与使用情况的专项报告（以下简称募集资金年度存放与使用情况专项报 告）执行了鉴证工作。 吉贝尔公司管理层的责任是按照上海证券交易所相关规定编制募集资金年度存放 与使用情况专项报告。这种责任包括设计、实施和维护与募集资金年度存放与使用情况 专项报告编制相关的内部控制，保证募集资金年度存放与使用情况专项报告的真实、准 确和完整，以及不存在由于舞弊或错误而导致的重大错报。我们的责任是在实施鉴证工 作的基础上，对募集资金年度存放与使用情况专项报告发表鉴证意见。 我们按照《中国注册会计师其他鉴证业务准则第 3101 号-历史财务信息审 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 194,231,470.59, representing a year-on-year increase of 17.47%[5] - Net profit attributable to shareholders was CNY 52,512,868.91, reflecting a growth of 38.15% compared to the same period last year[5] - Basic earnings per share increased by 40.00% to CNY 0.28[6] - Operating profit for Q1 2024 was ¥59,633,793.09, up 48.5% from ¥40,125,232.79 in Q1 2023[21] - Net profit attributable to shareholders for Q1 2024 was ¥52,512,868.91, representing a 38.3% increase from ¥38,010,611.11 in Q1 2023[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,213,111,571.85, a slight increase of 0.16% from the end of the previous year[6] - As of March 31, 2024, the total current assets amounted to RMB 1,104,740,362.42, a decrease from RMB 1,131,154,951.21 as of December 31, 2023, reflecting a decline of approximately 2.34%[17] - The total non-current assets reached RMB 1,108,371,209.43, up from RMB 1,078,513,262.02, marking an increase of approximately 2.76%[18] - Total liabilities as of Q1 2024 amounted to ¥247,660,490.12, down from ¥299,249,332.90 in the previous year[19] - The total liabilities included short-term borrowings of RMB 9,967,515.80, which is comparable to RMB 9,910,088.47 from the previous period[18] Cash Flow - The cash flow from operating activities was CNY 81,903,649.30, showing a decline of 20.22% year-on-year[5] - Cash flow from operating activities for Q1 2024 was ¥81,903,649.30, a decrease of 20.2% from ¥102,656,045.82 in Q1 2023[24] - Cash inflow from financing activities was 9,657,515.80, significantly higher than 1,160,185.00 in the previous year, marking an increase of approximately 731.5%[25] - The net cash increase for the period was -212,028,652.73, compared to -177,717,229.84 in the same period last year, representing a decline of approximately 19.2%[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,507[12] - The top shareholder, Zhenjiang Zhongtian Investment Consulting Co., Ltd., holds 28.77% of the shares, totaling 54,400,000 shares[12] Research and Development - Research and development expenses totaled CNY 9,696,429.60, accounting for 4.99% of operating revenue, a decrease of 0.17 percentage points[6] - Research and development expenses for Q1 2024 were ¥9,696,429.60, up 13.6% from ¥8,534,363.18 in Q1 2023[20] Other Financial Metrics - The weighted average return on equity increased by 0.5 percentage points to 2.72%[6] - The company reported a net profit excluding non-recurring gains and losses of CNY 51,784,574.69, up 37.25% year-on-year[5] - Accounts payable decreased to RMB 84,484,464.29 from RMB 91,218,635.80, showing a reduction of approximately 7.36%[18] - The company reported a significant decrease in employee compensation payable, which fell to RMB 10,578,531.22 from RMB 28,957,515.21, a decline of about 63.4%[18] Strategic Developments - There are no new strategies or product developments mentioned in the current report[16] - The company has not reported any significant changes in the top 10 shareholders or their participation in financing or margin trading activities[16] - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[25]

Financial Performance - The company's operating revenue for 2023 reached ¥860,933,244.79, representing a 31.49% increase compared to ¥654,730,646.35 in 2022[20]. - Net profit attributable to shareholders of the listed company was ¥219,087,891.18, a 41.65% increase from ¥154,667,820.31 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥209,137,599.61, up 49.99% from ¥139,432,351.71 in 2022[20]. - The company's total assets increased by 12.48% to ¥2,209,668,213.23 at the end of 2023, compared to ¥1,964,575,110.90 at the end of 2022[20]. - The weighted average return on net assets rose to 12.22%, an increase of 2.86 percentage points from 9.36% in 2022[21]. - The basic earnings per share for 2023 was ¥1.17, a 40.96% increase from ¥0.83 in 2022[21]. - The net cash flow from operating activities was ¥159,500,018.77, reflecting a 5.82% increase from ¥150,724,074.86 in the previous year[20]. - The company's net assets attributable to shareholders reached ¥1,904,838,829.13, a 12.82% increase from ¥1,688,429,785.82 at the end of 2022[20]. Research and Development - The company completed the IIb phase clinical trial for the antidepressant JJH201501, and the III phase trial is registered with the National Medical Products Administration[31]. - The company has obtained approval for the clinical trial of the anti-tumor drug JJH201601, which is currently undergoing phase I clinical research[31]. - The total R&D investment for the year was approximately ¥55.77 million, representing a 1.08% increase from the previous year[99]. - R&D investment as a percentage of operating income decreased from 8.43% to 6.48%, a reduction of 1.95 percentage points[99]. - The company has received 6 new patent applications and 4 patents granted during the reporting period, bringing the total to 52 applications and 28 granted patents[97]. - The company is developing new drugs targeting various diseases, including depression, tumors, and gastrointestinal issues, with a focus on innovative drug development[108]. - The company has established a research and development platform focusing on complex formulations, deuterated drugs, and liposome drug technologies[155]. Corporate Governance - The board of directors and senior management guarantee the authenticity and completeness of the annual report[6]. - There are no special arrangements for corporate governance applicable to the company[7]. - The company has established a robust internal control system to enhance operational efficiency and ensure compliance with legal regulations[184]. - The supervisory board, consisting of 3 members including one employee representative, operates in accordance with the law to protect shareholder rights[184]. - The company is committed to maintaining transparency and fairness in its operations, ensuring all shareholders, especially minority shareholders, are treated equitably[185]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with corporate governance regulations[185]. Operational Risks - The company is currently facing various operational risks, which are detailed in the risk factors section of the report[4]. - The company faces risks related to reliance on its main product, Likujun tablets, which significantly impacts future financial performance if competition increases[119]. - There is a risk of regulatory approval delays for new drug applications, which could affect the company's product pipeline and market position[120]. - The company is exposed to potential price reductions due to national drug procurement policies, which could adversely affect revenue and profitability[123]. Market and Product Development - The company attributed its revenue growth to enhanced product channel construction and promotion efforts, as well as increased sales of key products such as Licorice Tablets and Nicergoline Tablets[22]. - The company has a diverse product portfolio, including tablets, capsules, and eye drops, focusing on various therapeutic areas such as enhancing white blood cells and treating hypertension[38]. - The company's flagship product, Likujun tablets, is recognized for its effectiveness in treating leukopenia and has been included in the National Basic Medical Insurance Directory[40]. - The company is focusing on innovative drug development for diseases such as depression, tumors, and gastric diseases, expanding its product portfolio[76]. - The company is advancing multiple new drug candidates, including JJH201501 (antidepressant), JJH201601 (anticancer), and JJH201701 (anti-acid), enhancing its competitive position in the industry[109][111]. Financial Management - The company plans to suspend cash dividends and stock bonuses for the 2023 fiscal year, pending the completion of a stock issuance to specific investors[5]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures in providing guarantees[7]. - The company has not faced any significant issues regarding independence from its controlling shareholder or related party transactions[185]. - The company has no violations of its remuneration management system for directors, supervisors, and senior management during the reporting period[197]. Future Outlook - The company plans to enhance its innovation capabilities and focus on major disease areas such as oncology and cardiovascular diseases to improve its competitive position in the industry[177]. - In 2024, the company plans to strengthen its marketing system and expand sales channels, particularly for its cancer treatment product, Likujun tablets[179]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[196]. - New product launches are expected to contribute an additional 200 million yuan in revenue, with a focus on innovative drug formulations[193]. - The company is exploring potential acquisitions to strengthen its portfolio, with a budget of 500 million yuan allocated for this purpose[196].

国金证券股份有限公司 关于江苏吉贝尔药业股份有限公司 吉贝尔药业 JEBEL PHARM 2023年度以简易程序 向特定对象发行股票 之 上市保荐书 保荐人(主承销商) 国合证券股份有限公司 IK SECURITIES CO.,LTD. (成都市青羊区东城根上街 95 号) 二零二四年四月 江苏吉贝尔药业股份有限公司 上市保荐书 声 明 国金证券股份有限公司（以下简称"国金证券"、"保荐机构"或"保荐 人"）及其保荐代表人已根据《中华人民共和国公司法》（以下简称《公司法》） 《中华人民共和国证券法》（以下简称《证券法》）等法律法规和中国证监会及上 海证券交易所的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则和 行业自律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 3-2-1 江苏吉贝尔药业股份有限公司 上市保荐书 目 录 | 声 明. | | --- | | 月 求 … | | 释义… | | 第一节 本次证券发行基本情况 … | | 一、发行人基本信息 | | 二、主要经营和财务数据及指标 . | | 三、发行人存在的主要风险………………………………………………………………………………… ...

关于江苏吉贝尔药业股份有限公司 申请以简易程序向特定对象发行股票 | 9/F, Block A, Fu Hua Mansion, | | | | --- | --- | --- | | No. 8, Chao yangmen Beidajie, ineWing Dongcheng District, Beijing, | 传真: | +86(010)6554 7190 | | tified public accountants | 100027, P.R.China | facsimile: | +86(010)6554 7190 | 审核中心意见落实函的回复 XYZH/2024SHAA2F0014 江苏吉贝尔药业股份有限公司（以下简称"吉贝尔"、"发行人"或"公司"）拟申 请以简易程序向特定对象发行股票（以下简称"本次发行"）。信永中和会计师事务所（特 殊普通合伙）（以下简称"发行人会计师"或"我们"）作为吉贝尔本次发行的发行人会 计师，对落实意见中所提问题进行了认真讨论与核查，本着勤勉尽责、诚实守信的原则 就反馈意见所提问题逐条进行了回复，相关情况说明如下： 问题 1、关于本次募投项目 根据申报材料：（1 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2024-022 江苏吉贝尔药业股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年年度股东大会 召开日期时间：2024 年 5 月 20 日 14 点 00 分 召开地点：江苏省镇江市高新技术产业开发园区公司会议室 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 1 股东大会召开日期：2024年5月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 20 日 至 2024 年 5 月 20 日 东大会召开当 ...

国金证券股份有限公司 关于江苏吉贝尔药业股份有限公司 2023 年度募集资金存放与使用情况的核查意见 国金证券股份有限公司（以下简称"国金证券""保荐机构"）作为江苏吉贝 尔药业股份有限公司（以下简称"吉贝尔""公司"）首次公开发行股票并在科创 板上市及进行持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证 券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》等有关法律法规和规范性文件的要求，对吉贝尔 2023 年度募集资金存放与使用情况进行了核查，具体情况如下： 一、募集资金基本情况 （一）募集资金金额及到位时间 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意江苏吉贝 尔药业股份有限公司首次公开发行股票注册的批复》（证监许可[2020]614 号）同 意，公司首次公开发行人民币普通股（A 股）4,673.54 万股，每股面值 1.00 元， 每股发行价格为 23.69 元。本次公开发行募集资金总额为人民币 1,107,161,626.00 元，扣除各项发行费用人民币 ...

被提名人已经参加培训并取得证券交易所认可的相关培训证明 材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要 求: (一)《中华人民共和国公司法》等关于董事任职资格的规定; 独立董事提名人声明与承诺 提名人江苏吉贝尔药业股份有限公司董事会，现提名刘同君为江 苏吉贝尔药业股份有限公司第四届董事会独立董事候选人 , 并已充分 了解被提名人职业、学历、职称、详细的工作经历、全部兼职、有无 重大失信等不良记录等情况。被提名人已书面同意出任江苏吉贝尔药 业股份有限公司第四届董事会独立董事候选人(参见该独立董事候选 人声明)。提名人认为，被提名人具备独立董事任职资格，与江苏吉 贝尔药业股份有限公司之间不存在任何影响其独立性的关系，具体声 明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、规章及其他规范性文件，具有五年以上法律、经济、会计、 财务、管理等履行独立董事职责所必需的工作经验。 （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 (如适用); （三）中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及公司章程有关独立董事任职资格和条件的相 关规 ...

调整前： 根据本次发行的竞价结果，本次发行股票数量为 11,204,881 股，不超过本次 发行前公司总股本的 30%，对应募集资金金额不超过三亿元且不超过最近一年 末净资产百分之二十。 本次发行的具体认购情况如下： 证券代码：688566 证券简称：吉贝尔 公告编号：2024-013 江苏吉贝尔药业股份有限公司 关于 2023 年度以简易程序向特定对象发行 A 股股票 方案、预案修订情况说明的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2024 年 4 月 24 日，江苏吉贝尔药业股份有限公司（以下简称"公司"）召 开第四届董事会第五次会议、第四届监事会第五次会议，审议通过了《关于公司 以简易程序向特定对象发行股票预案（二次修订稿）的议案》(以下简称《预案》) 《关于调整公司以简易程序向特定对象发行股票方案的议案》等与 2023 年度以 简易程序向特定对象发行 A 股股票相关议案。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券发 行注册管理办法》等有关法律法规、规范性文件和公司 2022 年 ...

独立董事候选人声明与承诺 本人范明, 已充分了解并同意由提名人江苏吉贝尔药业股份有限 公司董事会提名为江苏吉贝尔药业股份有限公司第四届董事会独立 蓄事候选人。本人公开声明，本人具备独立董事任职资格，保证不存 在任何影响本人担任江苏吉贝尔药业股份有限公司独立董事独立性 的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识,熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有五年以上法律、经济会计、财 务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： (一)《中华人民共和国公司法》等关于董事任职资格的规定; （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 (如适用): （三）中国证监会《上市公司独立董事管理办法》和上海证券交 易所自律监管规则有关独立董事任职资格和条件的相关规定; （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用）; （五）中共中央组织部《关于进一步规范党政领导干部在企业兼 职（任职）问题的意见》的相关规定（ ...